Treatments for COVID-19 – Harvard Health

Read Time:20 Minute, 19 Second

Time to stock up on zinc?
Recent study shows more complications with alternative prostate biopsy method
Walnuts: A worthy addition to your daily diet?
What it takes to achieve world-changing scientific breakthroughs
Do weighted blankets help with insomnia?
Careful! Health news headlines can be deceiving
Why is topical vitamin C important for skin health?
Preventing preeclampsia may be as simple as taking an aspirin
Caring for an aging parent? Tips for enjoying holiday meals
A conversation about reducing the harms of social media

Most people who become ill with COVID-19 will be able to recover at home. Some of the same things you do to feel better if you have the flu — getting enough rest, staying well hydrated, and taking medications to relieve fever and aches and pains — also help with COVID-19.
Beyond that, the FDA has also authorized treatments that may be used for people who have been hospitalized with COVID-19 and other medications to curb the progression of COVID-19 in people who are not hospitalized but who are at risk for developing severe illness. Scientists continue working hard to develop other effective treatments.
At least two oral antiviral drugs have performed well in clinical trials and show promise in reducing the risk of COVID-related hospitalization and death.
In October 2021, Merck released promising study results about an oral antiviral drug to treat COVID-19. Compared to placebo, the antiviral drug, called molnupiravir, significantly reduced the risk of hospitalization and death in people with mild or moderate COVID-19 who were at high risk for severe COVID. Molnupiravir is under review by the FDA, which is scheduled to meet in late November to discuss whether the drug should be granted emergency use authorization (EUA).
The study results were based on data from 775 study participants from the US and around the world. To be eligible for the study, the participants had to have been diagnosed with mild-to-moderate COVID-19, have started experiencing symptoms no more than five days prior to their enrollment in the study, and have at least one risk factor that put them at increased risk for a poor outcome from COVID-19. None of the participants were hospitalized at the time they entered the study. About half of the study participants took the antiviral drug molnupiravir; four capsules, twice a day, for five days, by mouth. The remaining study participants took a placebo.
Patients taking molnupiravir were half as likely to be hospitalized or die from COVID-19 as those taking a placebo. Over the 29-day study period, 28 out of 385, or 7.3%, of participants who took molnupiravir were hospitalized, and no one in this group died. In the placebo group, 53 out of 377, or 14.1%, of participants were hospitalized, including eight participants in this group who died. The antiviral drug was effective against several COVID variants, including the Delta variant.
The study was randomized, placebo-controlled, and double-blind — the gold standard in study design. The results were announced in a press release and have not been peer-reviewed or published in a medical journal. According to the press release, the risk of adverse events and drug side effects was comparable in the molnupiravir and placebo groups.
Molnupiravir was developed by Merck and Ridgeback Biotherapeutics. It works by interfering with the COVID virus’s ability to replicate.
Interim study results released by Pfizer in a press release in November 2021 showed that its oral antiviral treatment, called Paxlovid, significantly reduced the risk of COVID-related hospitalization and death compared to a placebo. The company plans to ask the FDA to authorize the treatment.
The phase 2/3 study was randomized, double-blind, and placebo controlled. Study participants had symptomatic, confirmed early COVID-19, were at increased risk for severe illness due to age or an underlying medical condition, and were not hospitalized. They took either a placebo or the Paxlovid treatment twice a day for five days.
By 28 days after treatment, those who had taken Paxlovid within three days of symptom onset had an 89% reduced risk of COVID-related hospitalization or death compared to those who took a placebo. Study participants who started Paxlovid within five days of the start of symptoms had an 85% reduced risk compared to placebo. Side effects of Paxlovid and placebo were comparable, and generally mild. In consultation with the FDA, an independent committee recommended that the study be stopped early because of the apparent benefit of the treatment.
Paxlovid is a protease inhibitor antiviral therapy made up of a medicine called PF-07321332 and the HIV drug ritonavir. PF-07321332 was developed by Pfizer; it interferes with the ability of the coronavirus to replicate. Ritonavir slows the breakdown of PF-0732332 so that it remains active longer at higher amounts.
The prospect of having an oral antiviral to combat COVID-19 is exciting, but is not a substitute for getting vaccinated. The COVID vaccine remains more important than ever. We need layers of defense against this viral threat. Hopefully oral antiviral medications will be part of that defense.
A large study published in Lancet Global Health in October 2021 found that the antidepressant fluvoxamine (Luvox), which may be taken by mouth at home, significantly reduces the risk of hospitalization in some COVID-19 patients at serious risk for severe illness.
The Lancet study enrolled nearly 1,500 adults in Brazil. Most study participants were unvaccinated, had symptomatic, early, confirmed COVID-19, and were at increased risk of serious illness due to underlying health problems. About half took a placebo while the other half were told to take one 100-mg fluvoxamine pill, twice a day, for 10 days.
The fluvoxamine group was significantly less likely than the placebo group (11% versus 16%) to need hospitalization or an extended emergency room stay. The randomized, placebo-controlled trial was conducted by an international team of researchers, and it confirmed preliminary findings published last year in JAMA.
Common side effects of fluvoxamine include headaches, nausea, diarrhea, dizziness, and sexual side effects. In the Lancet trial, tens of participants assigned to fluvoxamine stopped taking the drug because of side effects. In addition, because the study participants took the drug (or placebo) at home, they did not all take the medication as prescribed. But in this case, medication adherence made a difference: those who took fluvoxamine as directed on more than 80% of possible days were significantly less likely to die than those in the placebo group. But there was no significant difference between the number of people who died in the placebo group compared to the full fluvoxamine group, which included a wide range of adherence.
Fluvoxamine is in a class of antidepressants called selective serotonin reuptake inhibitors (SSRIs). It was approved by the FDA in 1994 and is used to treat obsessive-compulsive disorder (OCD) and anxiety. Fluvoxamine appears to work against COVID by reducing inflammation, which is a hallmark of severe COVID infection. The drug may also have antiviral properties. Because it is already on the market, doctors can prescribe it off-label for COVID patients they deem appropriate.
Additional, high-quality research will hopefully reproduce the Lancet study findings and answer remaining questions. For example, will fluvoxamine help symptomatic COVID patients who are vaccinated, or those who do not have risk factors for severe illness? And, will people who already take daily fluvoxamine to treat mental health issues also gain some protection against COVID-19?
In November 2020, the FDA granted emergency use authorization to two monoclonal antibody treatments (bamlanivimab, made by Eli Lilly; and a combination of casirivimab and imdevimab, made by Regeneron). Both treatments have been approved for non-hospitalized adults and children over age 12 with mild to moderate COVID-19 symptoms who are at risk for developing severe COVID-19 or being hospitalized for it. In these patients, the approved treatments can reduce the risk of hospitalization and emergency room visits. These therapies must be given intravenously (by IV) soon after developing symptoms.
If you are recovering at home, these measures can help reduce symptoms:
Many doctors, including those in the United States, have been treating very ill COVID-19 patients with corticosteroids since the pandemic began. It makes biologic sense for those patients who have developed a hyper-immune response (a cytokine storm) to the viral infection. In these cases, it is the immune system’s overreaction that is damaging the lungs and other organs, and too often leading to death.
Dexamethasone and other corticosteroids (prednisone, methylprednisolone) are potent anti-inflammatory drugs. They are readily available and inexpensive.
The NIH COVID-19 treatment guidelines recommend the use of dexamethasone in certain people hospitalized with severe COVID-19. The recommendation was based on results from the RECOVERY trial. In the study, more than 6000 patients hospitalized with COVID-19 randomly received either dexamethasone or standard treatment. Patients who required supplemental oxygen or ventilators and who received dexamethasone were less likely to die within 28 days than those who received standard care. Dexamethasone did not have a benefit in patients who did not need respiratory support.
The FDA has granted emergency use authorization (EUA) for tocilizumab (Actemra) for the treatment of hospitalized adults and children ages 2 years and older who are receiving systemic corticosteroids such as dexamethasone, and who require supplemental oxygen, mechanical ventilation, or a heart-lung bypass machine, also known as extracorporeal membrane oxygenation (ECMO). Tocilizumab is a monoclonal antibody, already FDA-approved to treat several autoimmune diseases.
Some COVID patients get sicker because of an overreaction of the body’s immune response (a cytokine storm) to the viral infection. When this happens, the body overproduces interleukin-6 (IL-6) — a protein involved in inflammation — in lung cells. Tocilizumab blocks the action of IL-6, and thereby dampens the exaggerated immune system response.
The EUA was based on four clinical trials of hospitalized patients with COVID-19, which compared the use of tocilizumab plus routine care for COVID-19 (including corticosteroid therapy) to usual care alone. Through 28 days of follow up, tocilizumab plus usual care reduced the risk of death and the risk of being placed on a ventilator, and decreased the amount of time patients remained in the hospital, compared to usual care alone.
Tocilizumab is not authorized for use in non-hospitalized patients with COVID-19.
In October 2020, the FDA approved the antiviral drug remdesivir to treat COVID-19. The drug may be used to treat adults and children ages 12 and older and weighing at least 88 pounds, who have been hospitalized for COVID-19. Clinical trials suggest that in these patients, remdesivir may modestly speed up recovery time.
Baricitinib in combination with remdesivir
In November 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the use of baricitinib in combination with remdesivir in hospitalized adults and children two years and older who require respiratory support. However, there is not yet enough evidence to support the use of this therapy instead of dexamethasone with or without remdesivir.
Anticoagulation drugs (“blood thinners”)
Almost all people admitted to the hospital with COVID receive medications to help prevent blood clots. Doctors usually prescribe low dose heparin or enoxaparin. However, some patients require full doses of anticoagulants if they already have developed blood clots or have a high risk of doing so. Doctors always need to balance the risk of dangerous bleeding when prescribing full doses.
Three monoclonal antibody treatments for COVID-19 have been granted emergency use authorization (EUA) by the FDA. The treatments may be used to treat non-hospitalized adults and children over age 12 with mild to moderate symptoms who have recently tested positive for COVID-19, and who are at risk for developing severe COVID-19 or being hospitalized for it. This includes people over 65, people with obesity, and those with certain chronic medical conditions. Newer research suggests that monoclonal antibody treatment may also help to save lives in a specific subgroup of hospitalized COVID-19 patients.
Monoclonal antibodies are manmade versions of the antibodies that our bodies naturally make to fight invaders, such as the SARS-CoV-2 virus. All three of the FDA-authorized therapies attack the coronavirus’s spike protein, making it more difficult for the virus to attach to and enter human cells.
The monoclonal antibody treatments that have EUA approval are: a combination of casirivimab and imdevimab, called REGN-COV, made by Regeneron; a combination of bamlanivimab and etesevimab, made by Eli Lilly; and sotrovimab, made by GlaxoSmithKline. These treatments must be given intravenously in a clinic or hospital. These treatments are not currently authorized for hospitalized COVID-19 patients or those receiving oxygen therapy.
However, a pre-peer reviewed study, published in June 2021, showed promise for monoclonal antibody treatment in hospitalized COVID-19 patients who did not mount their own immune response. The study compared Regeneron’s monoclonal antibody treatment plus usual care to usual care alone in people hospitalized with COVID-19. In people who had not produced their own antibodies against the SARS-CoV-2 virus, monoclonal antibody treatment reduced the chances of dying by 20%. Monoclonal antibodies did not benefit people whose immune systems had already created antibodies in response to the virus.
Monoclonal antibodies also can be used in combination with corticosteroids, such as dexamethasone, to dampen the immune response in very ill hospitalized patients. Some COVID patients get sicker because of an overreaction of the body’s immune response (a cytokine storm) to the viral infection. When this happens, the body overproduces interleukin-6 (IL-6) — a protein involved in inflammation — in lung cells. The FDA has granted EUA for tocilizumab (Actemra), a monoclonal antibody that blocks the action of IL-6, and thereby dampens the exaggerated immune system response.
When people recover from COVID-19, their blood contains antibodies that their bodies produced to fight the coronavirus and help them get well. Antibodies are found in plasma, a component of blood.
Convalescent plasma — literally plasma from recovered patients — has been used for more than 100 years to treat a variety of illnesses from measles to polio, chickenpox, and SARS. It is widely believed to be safe.
In August 2020, the FDA issued an emergency use authorization (EUA) for convalescent plasma in patients hospitalized with COVID-19.
A small but well-designed trial (randomized, double-blind, and placebo-controlled) was published in the New England Journal of Medicine in January 2021. The study only enrolled patients 65 years and older, and researchers screened the convalescent plasma to ensure it contained high levels of antibodies. The researchers found that patients who received convalescent plasma within three days of developing symptoms were 48% less likely to develop severe COVID illness compared to patients who received placebo.
However, a meta-analysis of four peer-reviewed and published randomized clinical trials, published in JAMA, had less-promising results. The trials included in the analysis included 1060 patients with COVID-19 who received either convalescent plasma, a placebo, or standard treatment. Compared to placebo and standard treatment, convalescent plasma did not significantly improve risk of death, length of hospital stay, or the need for a ventilator. The study authors noted that the studies used for this analysis were small, and future clinical trials might suggest more benefit from the therapy.
In order to donate plasma, a person must meet several criteria. They have to have tested positive for COVID-19, recovered, have no symptoms for 14 days, currently test negative for COVID-19, and have high enough antibody levels in their plasma. A donor and patient must also have compatible blood types. Once plasma is donated, it is screened for other infectious diseases, such as HIV.
Each donor produces enough plasma to treat one to three patients. Donating plasma should not weaken the donor’s immune system nor make the donor more susceptible to getting reinfected with the virus.
An antiviral drug must be able to target the specific part of a virus’s life cycle that is necessary for it to reproduce. In addition, an antiviral drug must be able to kill a virus without killing the human cell it occupies. And viruses are highly adaptive. Because they reproduce so rapidly, they have plenty of opportunity to mutate (change their genetic information) with each new generation, potentially developing resistance to whatever drugs or vaccines we develop.
In June 2021, the US government announced that it will invest more than $3 billion to develop antiviral medications to treat COVID-19 and to prepare for future pandemic threats. The money will be used to speed up the development and testing of antiviral drugs that are already in clinical trials, and for additional drug discovery with a focus on medications that can be taken by mouth. While COVID-19 vaccines remain central to protection, antiviral medications may be important for people whose bodies do not mount a strong response to the vaccine, who experience breakthrough infections, and for those who are unvaccinated.
Some French doctors advise against using ibuprofen (Motrin, Advil, many generic versions) for COVID-19 symptoms based on reports of otherwise healthy people with confirmed COVID-19 who were taking an NSAID for symptom relief and developed a severe illness, especially pneumonia. These are only observations and not based on scientific studies.
The WHO initially recommended using acetaminophen instead of ibuprofen to help reduce fever and aches and pains related to this coronavirus infection, but now states that either acetaminophen or ibuprofen can be used. Rapid changes in recommendations create uncertainty. Since some doctors remain concerned about NSAIDs, it still seems prudent to choose acetaminophen first, with a total dose not exceeding 3,000 milligrams per day.
However, if you suspect or know you have COVID-19 and cannot take acetaminophen, or have taken the maximum dose and still need symptom relief, taking over-the-counter ibuprofen does not need to be specifically avoided.
Hydroxychloroquine is primarily used to treat malaria and several inflammatory diseases, including lupus and rheumatoid arthritis. It is inexpensive and readily available.
Early reports from China and France were promising, suggesting that patients with severe symptoms of COVID-19 improved more quickly when given hydroxychloroquine.
However, in an article published in December 2020 in JAMA, researchers reported that hydroxychloroquine did not result in any clinical benefits for adults hospitalized with respiratory illness from COVID-19, compared with placebo. The NIH treatment guidelines recommend against the use of hydroxychloroquine for COVID-19, in both hospitalized and non-hospitalized patients.
There is no evidence that taking high-dose vitamin D protects you against getting infected with this coronavirus. In addition, if you are infected, it does not prevent a more severe illness.
However, most studies looking at people at people hospitalized with COVID-19 found that having an abnormally low vitamin D blood level was associated with a worse outcome, including death, compared to patients with a normal blood level. These studies are observational only, meaning they only show a link between low vitamin D levels and a higher risk of severe illness. This does not mean that the low level caused the worse outcome.
The best advice regarding COVID-19 is similar to what is recommended to maintain bone health – making sure you get enough vitamin D to meet standard requirements.
Our bodies make vitamin D when exposed to sunshine. Five to 10 minutes of sun exposure on some or most days of the week to the arms, legs, or back without sunscreen will enable you to make enough of the vitamin. Good food sources of vitamin D include fatty fish (such as tuna, mackerel, and salmon), foods fortified with vitamin D (such as dairy products, soy milk, and cereals), cheese, and egg yolks.
The recommended dietary dose of vitamin D is 600 IU each day for adults 70 and younger, and 800 IU each day for adults over 70. For adults, the risk of harmful effects increases above 4,000 IU per day.
Some critically ill patients with COVID-19 have been treated with high doses of intravenous (IV) vitamin C in the hope that it will hasten recovery. However, there is no clear or convincing scientific evidence that it works for COVID-19 infections, and it is not a standard part of treatment for this infection.
Regarding prevention, there is no evidence that taking vitamin C will help prevent infection with the coronavirus that causes COVID-19. While standard doses of vitamin C are generally harmless, high doses can cause a number of side effects, including nausea, cramps, and an increased risk of kidney stones.
A serologic test is a blood test that looks for antibodies created by your immune system. There are many reasons you might make antibodies, the most important of which is to help fight infections. The serologic test for COVID-19 specifically looks for antibodies against the COVID-19 virus.
Your body takes at least one to three weeks after you have acquired the infection to develop antibodies to this virus. For this reason, serologic tests are not sensitive enough to accurately diagnose an active COVID-19 infection, even in people with symptoms.
However, serologic tests can help identify anyone who has recovered from coronavirus. This may include people who were not initially identified as having COVID-19 because they had no symptoms, had mild symptoms, chose not to get tested, had a false-negative test, or could not get tested for any reason. Serologic tests will provide a more accurate picture of how many people have been infected with, and recovered from, coronavirus, as well as the true fatality rate.
Serologic tests may also provide information about whether people become immune to coronavirus once they’ve recovered and, if so, how long that immunity lasts.
The accuracy of serologic tests varies depending on the test and when in the course of infection the test is performed.
Do vitamin D, zinc, and other supplements help prevent COVID-19 or hasten healing?
You’ve probably heard the anti-malarial drug hydroxychloroqine is getting a hard look as a potential therapeutic agent in the fight against COVID-19. However, as Harvard Health Publishing senior faculty editor Dr. Rob Shmerling points out, evidence remains weak. On the brighter side, he points to three potential avenues in COVID-19 research where therapies may be put to use while a vaccine remains in development.
Visit our  Coronavirus Resource Center  for more information on coronavirus and COVID-19.
Image: fizkes/Getty Images
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
Diseases & Conditions
Diseases & Conditions
Diseases & Conditions
You might also be interested in…
Any given year, we’ll collectively come down with one billion colds and up to 45 million cases of flu, while the number of new cases of COVID-19 keeps rising. In this guide, you will learn how to avoid getting any of these three viral infections, and, if you do get sick, what you can do to feel better. You’ll also learn when your condition is serious enough to call a doctor. The report also provides specific information about high-risk groups for whom COVID and the flu can be very serious.
Get the latest in health news delivered to your inbox!
© 2021 by The President and Fellows of Harvard College
Do not sell my personal information | Privacy Policy
Thanks for visiting. Don’t miss your FREE gift.
The Best Diets for Cognitive Fitness, is yours absolutely FREE when you sign up to receive Health Alerts from Harvard Medical School
Sign up to get tips for living a healthy lifestyle, with ways to fight inflammation and improve cognitive health, plus the latest advances in preventative medicine, diet and exercise, pain relief, blood pressure and cholesterol management, and more.
Health Alerts from Harvard Medical School
Get helpful tips and guidance for everything from fighting inflammation to finding the best diets for weight loss…from exercises to build a stronger core to advice on treating cataracts. PLUS, the latest news on medical advances and breakthroughs from Harvard Medical School experts.

0 %
0 %
0 %
0 %
0 %
0 %

Average Rating

5 Star
4 Star
3 Star
2 Star
1 Star

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous post Steris looks to open 121-job facility in Concord – Charlotte Business Journal – Charlotte Business Journal
Next post Study IDs Predictors of Emergency Hyperkalemia in HD Population – Renal and Urology News